Detalles de la búsqueda
1.
Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent headache or persistent post-traumatic headache in the majority of cases.
Cephalalgia
; 43(6): 3331024231182126, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37317535
2.
Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17-30 months.
J Headache Pain
; 24(1): 5, 2023 Jan 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36647006
Resultados
1 -
2
de 2
1
Próxima >
>>